Evidence map›Paper›PMID 37248319›Full record

ArticleJournal of cancer research and clinical oncology2023

Model for predicting prognosis and immunotherapy based on CD

Wei Bao, Zhiping Song, Hao Wan, Xiaoping Yu, Zhaoyan Chen, Yaqing Jiang, Xiao Chen, Kai Le

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Wei Bao *Department of Rehabilitation Medicine, The First Affiliated Hospital of Nanchang University, No.17 Yongwaizheng Street, Nanchang, 330006, Jiangxi Province, China.
Zhiping Song *Department of Anesthesia, The First Affiliated Hospital of Nanchang University, No.17 Yongwaizheng Street, Nanchang, 330006, Jiangxi Province, China.
Hao WanDepartment of General Surgery, Jiangxi Provincial Children's Hospital, No.122 Yangming Road, Nanchang, 330006, Jiangxi Province, China.
Xiaoping YuDepartment of Rehabilitation Medicine, The First Affiliated Hospital of Nanchang University, No.17 Yongwaizheng Street, Nanchang, 330006, Jiangxi Province, China.
Zhaoyan ChenDepartment of Rehabilitation Medicine, The First Affiliated Hospital of Nanchang University, No.17 Yongwaizheng Street, Nanchang, 330006, Jiangxi Province, China.
Yaqing JiangDepartment of Rehabilitation Medicine, The First Affiliated Hospital of Nanchang University, No.17 Yongwaizheng Street, Nanchang, 330006, Jiangxi Province, China.
Xiao ChenDepartment of Pediatrics, The First Affiliated Hospital of Nanchang University, No.17 Yongwaizheng Street, Nanchang, 330006, Jiangxi Province, China. ever1991@126.com.
Kai LeDepartment of Rehabilitation Medicine, The First Affiliated Hospital of Nanchang University, No.17 Yongwaizheng Street, Nanchang, 330006, Jiangxi Province, China. 230179294@seu.edu.cn.ORCID http://orcid.org/0000-0002-7625-2920
Nanchang University · CNJiangxi Provincial Children's Hospital · CN

Funding

National Natural Science Foundation of China 82060290the Natural Science Foundation of Jiangxi Province 20212BAB216040the Science and Technology Planed Projects of Jiangxi Provincial Health Commission 202110021
6 · The paper itself

Abstract

backgroundNeuroblastoma (NBL) is an extracranial malignant tumor in children deriving from the neural crest in the sympathetic nervous system. Although various immunotherapy interventions have made significant breakthroughs in many adult cancers, the efficacy of these immunotherapies was still limited in NBL. NBL has low immunogenicity which results in a lack of tumor-infiltrating T lymphocytes in the tumor microenvironment (TME). Moreover, tumor cells can wield many immune evasion strategies both in the TME and systemically to impede lymphocyte infiltration and activation. All these factors hamper the anti-tumor effects of CD8 MATERIALS AND

methodsIn this study, we utilized multidimensional bioinformatic methods to establish a risk model based on CD8

resultsWe obtained 33 CD8

conclusionsAccording to our analyses, the constructed CD8

Indexed as

CD8-Positive T-LymphocytesNeuroblastomaADAM ProteinsAdultChildHumansImmunotherapyMembrane ProteinsPrognosisTranscriptional Elongation FactorsTumor MicroenvironmentADAM9 protein, humanADAM ProteinsELL2 protein, humanMembrane ProteinsTranscriptional Elongation FactorsCD8+ T cells-related genesImmunotherapyNeuroblastoma (NBL)PrognosisTumor microenvironment (TME)

Identifiers

PMID37248319
PMCPMC11797743
OpenAlexW4378672723

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.